Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer
Pharmaceuticals · 31.03.2025 · 18 (4) · 511
DOI: 10.3390/ph18040511 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 31.03.2025. Verfasst von Jin Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430034, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Founda-tion of China, National Key R&D Program of China.
Abstract (Originalsprache)
Background
While Bacillus Calmette-Guérin (BCG) remains the first-line therapy for high-risk bladder cancer, 30–40% of patients develop treatment resistance necessitating radical cystectomy, some are not suitable candidates for this procedure. This underscores the critical need for novel therapeutic approaches. Emerging clinical evidence has increasingly supported the therapeutic potential of oncolytic viruses in bladder cancer treatment. Based on this clinical foundation, we investigated the anti-tumor effects of KD01, a novel type 5 recombinant oncolytic adenovirus previously developed by our team engineered to express truncated BID (tBID), in bladder cancer.
Methods
The cytotoxic effects and anti-tumor efficacy of KD01 were systematically evaluated across human bladder cancer cell lines, and cell death pathways were investigated by RNA sequencing and validated. Combination therapy studies with cisplatin employed cytotoxic testing. In the final stage, the safety of KD01 bladder instillation was evaluated.
Results
KD01 induced bladder cancer cell death through multiple mechanisms, including oncolysis, immunogenic cell death, and mitochondrial apoptosis. At higher doses, KD01 combined with cisplatin synergistically inhibited cancer cell proliferation and induced apoptosis. Additionally, KD01 amplified damage-associated molecular patterns (DAMPs) release and immune activation; the combination with cisplatin further enhanced the process. Safety evaluations showed favorable tolerance to intravesical perfusion with KD01.
Conclusions
The dual action of KD01 in directly killing tumor cells and activating anti-tumor immunity underscores its potential as a therapeutic agent. These findings highlight the preclinical efficacy and safety of KD01, informing the design of clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430034, China.
- National Clinical Research Centre for Obstetrics and Gynecology, Cancer Biology Research Centre (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and…
- Department of Neurosurgery, Tongji Hospital, Tongji Medical School, Huazhong University of Sciences and Technology, Wuhan 430030, China.
ORCID-Profile: Jin Guo, Fei Li, Yingyan Han
Förderung
- National Key R&D Program of China
- National Natural Science Founda-tion of China
- National Key R&D Program of China
- National Natural Science Foundation of China
Zitieren
APA
Guo, J., Xiong, S., Zhang, X., Gong, W., Si, Y., Ma, D., Li, F., & Han, Y. (2025). Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer. Pharmaceuticals, 18(4), 511. https://doi.org/10.3390/ph18040511
Vancouver
Guo J, Xiong S, Zhang X, Gong W, Si Y, Ma D, et al. Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer. Pharmaceuticals. 2025;18(4):511. doi:10.3390/ph18040511
BibTeX
@article{Guo2025,
author = {Guo, Jin and Xiong, Shengfeng and Zhang, Xinyuan and Gong, Wei and Si, Yao and Ma, Ding and Li, Fei and Han, Yingyan},
title = {Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {4},
pages = {511},
doi = {10.3390/ph18040511}
}
EUVIMED